

Serial No. 10/602,215
PC 21501B

Please replace all prior claims in the application with the following:

Claim 1 (currently amended): A liquid pharmaceutical composition comprising:
~~a gamma-aminobutyric acid (GABA) analog~~ an amino acid selected from the
group consisting of gabapentin and pregabalin;[[,]]

one or more polyhydric alcohols, each containing 2 to 6 carbon atoms;[[,]] and
water;[[,]]

wherein the one or more polyhydric alcohols comprises about 25 g to about 75 g
per 100 mL of the composition and the composition has a pH of about 5.5 to about 7.0.

Claim 2 (previously presented): The composition according to claim 1, wherein
the one or more polyhydric alcohols each contains 3 to 5 carbon atoms.

Claim 3 (previously presented): The composition according to claim 1, wherein
the one or more polyhydric alcohols are selected from the group consisting of: glycerol,
xylitol, sorbitol, mannitol, and mixtures thereof, and wherein the one or more polyhydric
alcohols comprises about 40 g to about 75 g per 100 mL of the composition.

Claim 4 (original): The composition according to claim 1, wherein the pH is about
6.0 to about 7.0.

Claim 5 (previously presented): The composition according to claim 1,
comprising one or both of: a preservative and a flavor improver, wherein the flavor
improver does not contain an aldehyde or keto functionality.

Claim 6 (currently amended): A method for preparing a liquid pharmaceutical
composition containing an amino acid selected from the group consisting of gabapentin
and pregabalin, the method comprising: adding one or more polyhydric alcohols, each
containing 2 to 6 carbon atoms, to water to form a first solution; adding ~~a gamma-~~
~~aminobutyric acid analog selected from gabapentin and pregabalin~~ the amino acid to the
first solution to form a second solution; and optionally adjusting the pH of the second
solution to about 5.5 to about 7.0 to afford the liquid pharmaceutical composition,

Non-Final Amendment Page 2 of 8

Serial No. 10/602,215
PC 21501B

wherein the one or more polyhydric alcohols comprises about 25 g to about 75 g per 100 mL of the composition.

Claim 7 (previously presented): The method according to claim 6, wherein the one or more polyhydric alcohols is a mixture of glycerol and xylitol.

Claim 8 (previously presented): The method according to claim 6, wherein the pH of the composition is about 6 to about 7.

Claim 9 (currently amended): A liquid pharmaceutical composition containing an amino acid selected from the group consisting of gabapentin and pregabalin, the composition comprising a first component, the first component comprising a powder mixture of ~~a gamma-aminobutyric acid (GABA) analog selected from gabapentin and pregabalin~~ the amino acid and one or more solid polyhydric alcohols, and a second component comprising a liquid base, wherein the first and second components are combined to afford the liquid pharmaceutical composition in which the one or more polyhydric alcohols comprises about 25 g to about 75 g per 100 mL of the composition.

Claim 10 (currently amended): A method for preparing a liquid pharmaceutical composition containing an amino acid selected from the group consisting of gabapentin and pregabalin, the method comprising: mixing ~~a gamma-aminobutyric acid (GABA) analog selected from gabapentin and pregabalin~~ the amino acid with a first solid polyhydric alcohol to afford a powder mixture; mixing a second polyhydric alcohol with a sweetener and a flavor in water to afford a liquid base; and adding the powder mixture to the liquid base to afford the liquid pharmaceutical composition, wherein the first and second polyhydric alcohols may be the same or different and together comprise about 25 g to about 75 g per 100 mL of the composition.

Claim 11 (currently amended): The method according to claim 10, wherein the ~~GABA analog~~ amino acid is gabapentin.

Non-Final Amendment Page 3 of 8

Serial No. 10/602,215
PC 21501B

Claim 12 (currently amended): The composition according to claim 1 or claim 9 wherein the ~~GABA analog~~ amino acid is gabapentin.

Claim 13 (currently amended): The composition according to claim 1 or claim 9 wherein the composition has less than 0.5% by weight of the corresponding lactam of the ~~GABA analog~~ amino acid.

Claim 14 (currently amended): ~~A liquid pharmaceutical~~ The composition of claim 1, wherein the amino acid is comprising gabapentin, water, and one or more polyhydric alcohols, each containing 2 to 6 carbon atoms, and the composition having a pH of about 5.5 to about 7.0 and containing contains less than 0.5% weight/weight of gabapentin lactam after storage at 2°C to 10°C for 18 months to 2 years, wherein the one or more polyhydric alcohols comprises at least 25 g per 100 mL of the composition.

Claims 15-17 (canceled)

Claim 18 (currently amended): ~~A liquid pharmaceutical~~ The composition comprising water, a gamma-aminobutyric acid analog which of claim 1, wherein the amino acid is gabapentin, and the one or more polyhydric alcohols is selected from the group consisting of xylitol, and glycerol and mixtures thereof, wherein the one or more polyhydric alcohols and comprises about 25 g to about 75 g per 100 mL of the composition, and the composition has a pH of about 5.5 to about 7.0.

Claim 19 (new): A method of treating a subject suffering from a cerebral disease, including epilepsy, faintness attacks, or hypokinesia; cranial trauma; a neurodegenerative disorder; depression; mania; bipolar disorder; anxiety; panic; inflammation; renal colic; insomnia; gastrointestinal damage; incontinence; migraine; or pain, including neuropathic pain, muscular pain, or skeletal pain, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 1, claim 14 or claim 18.

Non-Final Amendment Page 4 of 8